[Total body irradiation: present and future].
Total body irradiation (TBI) has an established role as preparative regimen for bone-marrow transplantation in the treatment of hematological malignancies. Many randomized trials demonstrated that the clinical outcomes obtained from the association of TBI and cyclophosphamide are equivalent, or, sometimes, better than those based on chemotherapeutic agents. Despite the therapeutic progress of the last years, and the consequent improvement in the overall survival, this preparative regimen remains always associated with a relatively high rate of acute and late toxicity. In this article, we review the actual indications of TBI in clinical practice, and analyze the technological progress in this domain. We focus on the hypothesis that a selective irradiation of the hematopoietic or lymphoid organs is actually possible with intensity-modulated radiotherapy. Technical limits and preliminary results in terms of acute and late toxicities of intensity-modulated TBI are analyzed. With these new technologies, treatment-related toxicity is not anymore a major limiting factor in the preparative regimens for bone-marrow transplantation, allowing for a larger spectrum of TBI indications, a possible extension to patients older than 50 years, or a dose escalation. Preliminary results warrant, however, further evaluation in clinical trials to better assess the impact of this new approach on disease control and the long-term toxicity.
Zilli
T
T
Service de radio-oncologie, hôpitaux universitaires de Genève, 24, 1211 Genève 14, Suisse. Thomas.Zilli@hcuge.ch
Miralbell
R
R
Ozsahin
M
M
D016026:Bone Marrow Transplantation; D003520:Cyclophosphamide / Q000627:therapeutic use; D005544:Forecasting; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects / Q000379:methods*; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D014916:Whole-Body Irradiation / Q000009:adverse effects / Q000379:methods / Q000639:trends*
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide